局限期小细胞肺癌的放疗与全身治疗
综述指出局限期小细胞肺癌标准治疗20余年未变,仍为4-6周期顺铂联合依托泊苷同步胸部放疗后对有效者行预防性颅脑照射。长期生存改善至中位25-30个月,约三分之一患者生存5年。CONVERT和CALGB 30610 III期试验未显示高剂量每日一次胸部放疗较标准45 Gy每日两次有生存优势。免疫治疗在局限期的作用正在研究中。
要点
- 局限期小细胞肺癌标准治疗为4-6周期顺铂联合依托泊苷同步胸部放疗,有效者后续行预防性颅脑照射。
- CONVERT和CALGB 30610 III期试验未显示高剂量每日一次胸部放疗较45 Gy每日两次有生存优势。
- 长期生存改善至中位25-30个月,约三分之一患者生存5年。
核心结论
- 局限期小细胞肺癌标准治疗20余年未发生显著改变。
- 长期结局有所改善,中位生存接近25-30个月,约三分之一患者生存5年。
- 高剂量每日一次胸部放疗较标准45 Gy每日两次未显示生存优势。
研究设计与样本
- 综述,未报告系统检索范围。
主要发现
- 标准治疗为4-6周期顺铂联合依托泊苷同步胸部放疗,有效者后续行预防性颅脑照射。
- 中位生存接近25-30个月,约三分之一患者生存5年。
- CONVERT和CALGB 30610 III期试验未显示高剂量每日一次胸部放疗较标准45 Gy每日两次胸部放疗有生存优势。
- 高剂量每日一次胸部放疗在临床实践中仍常见。
- 一项III期试验比较60 Gy每日两次胸部放疗与45 Gy每日两次胸部放疗,旨在验证II期研究中60 Gy每日两次的引人注目的结果。
临床怎么用
- 原文未据此给出推荐。
- 作者指出未来治疗的重大进展可能取决于更好地理解和利用小细胞肺癌的分子特征以实现日益个体化的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower pace than non-small-cell lung cancer. In fact, the standard treatment regimen for limited stage SCLC has not appreciably shifted in more than 20 years, consisting of four to six cycles of cisplatin and etoposide chemotherapy concurrent with thoracic radiotherapy (TRT) followed by prophylactic cranial irradiation (PCI) for responsive disease. Nevertheless, long-term outcomes have improved with median survival approaching 25-30 months, and approximately one third of patients now survive 5 years. This is likely attributable in part to improvements in staging, including use of brain magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography imaging, advances in radiation treatment planning, and supportive care. The CONVERT and CALGB 30610 phase III trials failed to demonstrate a survival advantage for high-dose, once-daily TRT compared with standard 45 Gy twice-daily TRT, although high-dose, once-daily TRT remains common in practice. A phase III comparison of high-dose 60 Gy twice-daily TRT versus 45 Gy twice-daily TRT aims to confirm the provocative outcomes reported with 60 Gy twice daily in the phase II setting. Efforts over time have shifted from intensifying PCI, to attempting to reduce treatment-related neurotoxicity, to more recently questioning whether careful magnetic resonance imaging surveillance may obviate the routine need for PCI. The addition of immunotherapy has resulted in mixed success in extensive-stage SCLC with modest benefit observed with programmed death-ligand 1 inhibitors, and several ongoing trials assess programmed death-ligand 1 inhibition concurrent or adjuvant to chemoradiotherapy in limited-stage SCLC. Major advances in future treatment will likely depend on a better understanding and exploiting of molecular characteristics of SCLC with increasing personalization of therapy.
引用
- Bogart JA, Waqar SN, Mix MD, et al. Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer. J Clin Oncol. 2022. PMID: 34985935. doi:10.1200/JCO.21.01639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。